Process of allocation
concealment:
|
The concealment of the random distribution scheme adopts the envelope random distribution method. The third-party personnel who do not participate in the trial put the random number cards into the sequentially coded, opaque and sealed envelopes one by one according to the generated random distribution sequence. After completing the screening of subjects and signing the informed consent, open the envelopes in turn according to the order of their visits, and obtain the drug number corresponding to the random grouping of subjects for corresponding treatment. The drug number of each subject was unique and remained unchanged throughout the trial.
|
Blinding:
|
This experiment is a double-blind, single simulation design. The placebo is consistent with the simulated experimental drug Erzhu Gastrodia elata granule in terms of dosage form, appearance, shape, color, outer packaging, etc. at the same time, the pharmacist who does not participate in the test process marks the random number on the drug packaging box in sequence, and the distribution table recording the serial number, drug number, random number and group mark is in duplicate, which is kept by the third party who does not participate in the test and the pharmacy respectively. Researchers should distribute drugs in strict accordance with the order of each visit and the drug number. Drugs should not be selected, and the number should remain stable throughout the test process.
The study adopted a two-stage double-blind design. In the case collection stage, neither the subjects nor the researchers knew the grouping of subjects. From the formulation of the scheme, the generation of random numbers, the preparation of the blind base, the allocation of drugs according to the blind base, the enrollment of subjects, the recording of test results by researchers, the evaluation and data management, all remain blind. All drug coding processes shall be written into documents by the blind editor, that is, blind records, which shall be kept as one of the documents of the clinical trial.
|
Rules of uncover or
ceasing blinding:
|
After all the research data are entered and locked, the researchers who keep the blind background will uncover the blindness and conduct statistical analysis according to the requirements of the statistical analysis plan. After completing the statistical analysis, write the statistical analysis report and clinical trial summary report.
|